I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb reported that in the Phase 3 EXCALIBER-RRMM trial, ZENBEXUS with daratumumab/dexamethasone achieved a 41.1% MRD-negative complete response rate versus 20.7% for DVd (p
Bristol Myers Squibb reported EXCALIBER-RRMM showed ZENBEXUS with daratumumab/dexamethasone achieved 41.1% MRD‑negative CR vs 20.7% with DVd (p<0.0001) at 15.7 months’ median follow-up in 420 patients. PFS, the co‑primary endpoint, is still being evaluated.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | MRD‑neg CR 41.1% vs 20.7% (p<0.0001) | Statistically significant efficacy signal supports accelerated approval path and potential adoption. |
| 2 | ORR 88.9% vs 76.1% | Higher response rates bolster clinical competitiveness vs standard DVd. |
| 3 | CR or better 45.9% vs 24.9% | Deeper responses can translate into longer disease control if sustained. |
| 4 | Safety: neutropenia Grade 3/4 84.3% vs 11.3% | High hematologic toxicity may limit use; requires management resources. |
| 5 | Lower neuropathy: 12.3% vs 42.6% | Less neuropathy vs bortezomib regimen may favor ZENBEXUS in practice. |
| 6 | PFS co‑primary ongoing (n=800) | Confirmatory PFS readout is key for full approval and broader uptake. |
Context by AI Analyst
This is a mid‑cycle clinical validation step, adding quantitative efficacy data after prior accelerated approval based on MRD‑neg CR. For a larger catalyst, the confirmatory PFS co‑primary endpoint must show superiority and support conversion to full approval.
Based on the original press release from Bristol Myers Squibb distributed by BusinessWire.